Suchergebnisse - "Podzamczer, Daniel"

PubPharm (305)

21

Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy

enthalten in: Biochemical pharmacology | 2021

von Vigón, L. | Martínez-Román, P. | Rodríguez-Mora, S. | +27

22

Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58)

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2021

von Imaz, A. | Tiraboschi, J. | Niubó, J. | +14

23

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection : 5-Year Results From the LATTE-2 Study

enthalten in: Open forum infectious diseases | 2021

von Smith, G. | Henry, W. | Podzamczer, D. | +18

24

Comparison of two sample collection devices for anal cytology in HIV-positive men who have sex with men : Cytology brush and Dacron swab

enthalten in: Cytopathology : official journal of the British Society for Clinical Cytology | 2021

von Silva-Klug, A. | Saumoy, M. | Baixeras, N. | +8

25

Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM) : a randomised non-inferiority trial

enthalten in: The lancet. HIV | 2021

von Rojas, J. | de Lazzari, E. | Negredo, E. | +14

CommentIn: Lancet HIV. 2021 Aug;8(8):e454-e455. - PMID 34358493

26

Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV

enthalten in: The Journal of antimicrobial chemotherapy | 2021

von González-Cordón, A. | Assoumou, L. | Moyle, G. | +117

27

Do All Integrase Strand Transfer Inhibitors Have the Same Lipid Profile? Review of Randomised Controlled Trials in Naïve and Switch Scenarios in HIV-Infected Patients

enthalten in: Journal of clinical medicine | 2021

von Saumoy, M. | Sanchez-Quesada, J. | Ordoñez-Llanos, J. | +1

28

Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis : week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial

enthalten in: The lancet. HIV | 2021

von Ogbuagu, O. | Ruane, P. | Podzamczer, D. | +118

ErratumIn: Lancet HIV. 2021 Dec;8(12):e734. - PMID 34571044

29

No Changes in Human Immunodeficiency Virus (HIV) Suppression and Inflammatory Markers in Cerebrospinal Fluid in Patients Randomly Switched to Dolutegravir Plus Lamivudine (Spanish HIV/AIDS Research Network, PreEC/RIS 62)

enthalten in: The Journal of infectious diseases | 2021

von Tiraboschi, J. | Rojas, J. | Zetterberg, H. | +10

30

Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19 : a multicentre cohort study

enthalten in: The Lancet. Infectious diseases | 2021

von Gutiérrez-Gutiérrez, B. | Del Toro, M. | Borobia, A. | +110

CommentIn: Lancet Infect Dis. 2021 Jun;21(6):744-745. - PMID 33636149